Table 2.

HH inhibitors in clinical trial, mainly focusing on lung cancer therapy.

Drug	Target	Number	Cancer Type	Clinical Trial	NCT trial	Status
Sonidegib	Smo	–	BCC	–	–	FDA
Vismodegib	Smo	–	BCC	–	–	FDA
Glasdegib	Smo	–	AML	–	–	FDA
Vismodegib (GDC-0449)	Smo	168	SCLC	Phase 2	NCT00887159	Completed
	Smo	67	Solid cancers	Phase 1	NCT00968981	Completed
	Smo	68	Unspecified adult solid tumor	Phase 1	NCT00607724	Completed
	Smo	63	Malignant neoplasm	Phase 1 Phase 2	NCT01174264	Completed
	Smo	31	Cancer	Phase 1	NCT01546519	Completed
	Smo	55	Adult solid neoplasm	Phase 1	NCT00878163	Active, not recruiting
	Smo	6452	Advanced malignant solid neoplasm	Phase 2	NCT02465060	Recruiting
Sonidegib (LDE225)	Smo	19	Lung cancer	Phase1	NCT01579929	Completed
	Smo	114	Advanced solid tumor	Phase 1	NCT01769768	Completed
	Smo	10	Ptch1 or Smo activated solid and hematologic tumors	Phase 2	NCT02002689	Terminated
	Smo	45	Advanced solid tumors	Phase 1	NCT01208831	Completed
	Smo	103	Advanced solid tumor cancers	Phase 1	NCT00880308	Completed
	Smo	30	Solid tumor	Phase 1	NCT01954355	Completed
PF-04449913	Smo	23	Solid cancers	Phase 1	NCT01286467	Completed
IPI-926 (Saridegib)	Smo	94	Neoplasms	Phase 1	NCT00761696	Completed
Itraconazole	Smo	17	NSCLC	Early phase 1	NCT02357836	Completed
	Smo	60	Lung cancer	Phase 1	NCT03664115	Unknown
Taladegib (LY2940680)	Smo	26	SCLC	Phase 1 Phase 2	NCT01722292	Terminated
	Smo	19	Neoplasm metastasis	Phase 1	NCT01919398	Completed
LEQ506		57	Advanced solid tumors	Phase 1	NCT01106508	Completed
BMS-833923		5	SCLC	Phase 1	NCT00927875	Completed
Arsenic Trioxide (ATO)	Gli	9	NSCLC	Phase 1	NCT02066870	Unknown
	Gli	30	Lung cancer	Phase 2	NCT00075426	Completed
	Gli	20	Lung cancer	Phase 2	NCT01470248	Completed
Simvastatin	Oxysterol	62	SCLC	Phase 2	NCT00452634	Completed
	Oxysterol	70	SCLC	Phase 2	NCT04698941	Not yet recruiting
	Oxysterol	110	Lung cancer	Phase 2	NCT00452244	Completed
	Oxysterol	192	SCLC	Phase 2	NCT01441349	Recruiting
	Oxysterol	84	NSCLC	Phase 2	NCT01156545	Unknown